Scott Mackey1, Jennifer L Stewart2, Colm G Connolly3, Susan F Tapert2, Martin P Paulus4. 1. Department of Psychiatry, University of California, San Diego, 8939 Villa La Jolla Drive suite 200, La Jolla, CA 92037, USA. Electronic address: msmackey@ucsd.edu. 2. Department of Psychiatry, University of California, San Diego, 8939 Villa La Jolla Drive suite 200, La Jolla, CA 92037, USA. 3. Department of Psychiatry, University of California, San Francisco, San Francisco, CA 94143, USA. 4. Department of Psychiatry, University of California, San Diego, 8939 Villa La Jolla Drive suite 200, La Jolla, CA 92037, USA; Veterans Affairs San Diego Healthcare System, La Jolla, CA 92037, USA.
Abstract
BACKGROUND: Although the interaction of brain volume with amphetamine-type stimulants (ATS) and cocaine has been investigated in chronically dependent individuals, little is known about structural differences that might exist in individuals who consume ATS and cocaine occasionally but are not dependent on these drugs. METHODS: Regional brain volumes in 165 college aged occasional users of ATS (namely: amphetamine, methamphetamine, methylphenidate, and 3,4-methylenedioxymethamphetamine; MDMA) and cocaine were compared by voxel-based morphometry with 48 ATS/cocaine-naive controls. RESULTS: Grey matter volume was significantly higher in the left ventral anterior putamen of occasional users, and lower in the right dorsolateral cerebellum and right inferior parietal cortex. A regression in users alone on lifetime consumption of combined ATS (namely: amphetamine, methamphetamine, methylphenidate and MDMA) and cocaine use revealed that individuals who used more ATS/cocaine had greater volume in the right ventromedial frontal cortex. A second regression on lifetime consumption of ATS with cocaine as a covariate revealed that individuals with a greater history of ATS use alone had more grey matter volume in the left mid-insula. Interestingly, structural changes in the ventromedial prefrontal cortex, insula and striatum have been consistently observed in volumetric studies of chronic ATS and cocaine dependence. CONCLUSION: The present results suggest that these three brain regions may play a role in stimulant use even in early occasional users.
BACKGROUND: Although the interaction of brain volume with amphetamine-type stimulants (ATS) and cocaine has been investigated in chronically dependent individuals, little is known about structural differences that might exist in individuals who consume ATS and cocaine occasionally but are not dependent on these drugs. METHODS: Regional brain volumes in 165 college aged occasional users of ATS (namely: amphetamine, methamphetamine, methylphenidate, and 3,4-methylenedioxymethamphetamine; MDMA) and cocaine were compared by voxel-based morphometry with 48 ATS/cocaine-naive controls. RESULTS: Grey matter volume was significantly higher in the left ventral anterior putamen of occasional users, and lower in the right dorsolateral cerebellum and right inferior parietal cortex. A regression in users alone on lifetime consumption of combined ATS (namely: amphetamine, methamphetamine, methylphenidate and MDMA) and cocaine use revealed that individuals who used more ATS/cocaine had greater volume in the right ventromedial frontal cortex. A second regression on lifetime consumption of ATS with cocaine as a covariate revealed that individuals with a greater history of ATS use alone had more grey matter volume in the left mid-insula. Interestingly, structural changes in the ventromedial prefrontal cortex, insula and striatum have been consistently observed in volumetric studies of chronic ATS and cocaine dependence. CONCLUSION: The present results suggest that these three brain regions may play a role in stimulant use even in early occasional users.
Authors: Teresa R Franklin; Ze Wang; Joshua Shin; Kanchana Jagannathan; Jesse J Suh; John A Detre; Charles P O'Brien; Anna Rose Childress Journal: Brain Struct Funct Date: 2013-01 Impact factor: 3.270
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell Journal: Psychopharmacology (Berl) Date: 2006-08-17 Impact factor: 4.530
Authors: N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; C Wong; J Logan Journal: Am J Psychiatry Date: 2001-03 Impact factor: 18.112
Authors: Karen D Ersche; Anna Barnes; P Simon Jones; Sharon Morein-Zamir; Trevor W Robbins; Edward T Bullmore Journal: Brain Date: 2011-06-20 Impact factor: 13.501
Authors: Anouk Schrantee; Lena Václavů; Dennis F R Heijtel; Matthan W A Caan; Willy Gsell; Paul J Lucassen; Aart J Nederveen; Jan Booij; Liesbeth Reneman Journal: Neuropsychopharmacology Date: 2015-03-13 Impact factor: 7.853
Authors: Sarah W Yip; Patrick D Worhunsky; Jiansong Xu; Kristen P Morie; R Todd Constable; Robert T Malison; Kathleen M Carroll; Marc N Potenza Journal: Addict Biol Date: 2017-02-01 Impact factor: 4.280
Authors: Kenneth Blum; Marcelo Febo; David E Smith; A Kenison Roy; Zsolt Demetrovics; Frans J Cronjé; John Femino; Gozde Agan; James L Fratantonio; Subhash C Pandey; Rajendra D Badgaiyan; Mark S Gold Journal: J Child Adolesc Psychopharmacol Date: 2015-04-28 Impact factor: 2.576
Authors: Hank P Jedema; Xiaowei Song; Howard J Aizenstein; Alexandra R Bonner; Elliot A Stein; Yihong Yang; Charles W Bradberry Journal: Biol Psychiatry Date: 2020-08-18 Impact factor: 13.382